NasdaqGS:TLRYPharmaceuticals
Tilray (TLRY) Is Down 5.9% After DOJ Nixes Cannabis Rules and Eyes Reverse Stock Split – Has the Bull Case Changed?
In recent days, Tilray Brands faced a setback as the Department of Justice canceled pending cannabis rules, causing regulatory uncertainty and prompting the company to consider measures such as a reverse stock split to meet Nasdaq listing standards.
This development comes as Tilray continues to report sizable net income losses and contends with mounting financial and compliance pressures within the competitive cannabis sector.
We'll explore how this regulatory reversal could affect Tilray...